Phase 4 N=43 Anti-inflammatory Therapy to Improve Outcomes After TPIAT
Pancreatitis, Chronic; Diabetes; Transplant
Primary: Maximal Acute C-peptide Response to Glucose (ACRmax) — 1.06; 1.52; 1.29 ng/mL*min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality
Chronic Pancreatitis · Insulin Resistance · Normal or Mildly Abnormal Stool Fat Levels
Primary: Glucose Tolerance at 24 Weeks — 2; 4; 3; 4 Participants
Phase 4 N=83 Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant
Pancreatitis · Diabetes
Primary: Insulin Independence — 42; 45 percentage of participants
Phase 2 N=48 Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis
Chronic Pancreatitis
Primary: Islet Graft Function — 233; 354 ng/ml*min
N/A N=177 Diabetes and Lipid Accumulationand Heart Transplant
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
Phase 2 N=7 Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation
Diabetes Mellitus, Type 1
Primary: Insulin Independence. — 2 Participants
Phase 4 N=6 Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
Nephrotoxicity
Primary: Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) — 2.25 ml/min/1.73m2
Phase 1 N=4 Pancreatic Islet Cell Transplantation
Type 1 Diabetes
Primary: Achievement of Insulin Independence at 12-month Post Transplant — 1 participant
Early Phase 1 N=11 Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes
Type 1 Diabetes
Primary: Improvement in Glucose Regulation — 34.42; 34.42; 35.44; 39.03 ng*hr/mL — p=0.43
N/A N=60 Hyperglycemia in Renal Transplantation
Diabetes · End Stage Renal Disease
Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants
Phase 4 N=36 A Clinical Trial to Prevent New Onset Diabetes After Transplantation
Prevention of New Onset Diabetes Among Kidney Transplant Patients
Primary: The Incidence of New Onset of Diabetes After Transplant (NODAT) 12 Months After Kidney Transplantation — 3; 1 Participants — p=0.87
Phase 2 N=7 Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients
Diabetes Mellitus, Type I
Primary: Insulin Independence With Both an HbA1c ≤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point…
Phase 2 N=36 Islet Transplantation for Type 1 Diabetes
Diabetes Mellitus, Insulin-Dependent
Primary: Percent of Participants That Achieved Insulin Independence With Adequate Control of Blood Glucose Levels at One Year Post Final Islet Transplantation. — 44; 14; 17; 14…
Phase 4 N=61 Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant
Posttransplant Diabetes Mellitus
Primary: 2-hour Oral Glucose Tolerance Test-derived Blood Sugar — 141.00; 165.22 mg/dL
Phase 2 N=8 Incretin Effect and Use After Clinical Islet Transplantation
Type 1 Diabetes
Primary: The Primary Endpoint Will be Insulin Independence After 6 Months of Therapy. — 0.25 proportion of participants — p=< 0.05
Phase 1 N=7 Autologous Adult Stem Cells to Patients With Type 1 Diabetes and a Successful Renal Transplant
Type 1 Diabetes · Type 2 Diabetes
Primary: Number of Participants Who Experienced Adverse Events — 1; 7 participants
Phase 2 N=8 Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free Immunosuppression
Diabetes Mellitus, Type 1
Primary: The Number of Insulin-Independent Subjects at One Year Following Islet Cell Transplantation — 5 participants
Phase 2 N=60 Fecal Microbiota Transplantation for Pancreatitis
Acute Pancreatitis · Intestinal Bacteria Flora Disturbance · Intestinal Dysfunction
Primary: Number of Participants With Gastrointestinal Failure Score Equal 0 — 12; 14 Participants
N/A N=148 SpHincterotomy for Acute Recurrent Pancreatitis
Pancreatitis · Pancreas Divisum · Pancreatitis, Acute
Primary: Reduce the Risk of Subsequent Acute Pancreatitis Episodes by 33% — 32; 26 Participants
Phase 2 N=5 Islet Transplantation Using Abatacept
Type 1 Diabetes Mellitus
Primary: The Number of Insulin-independent Subjects at Day 75 (± 5 Days) Following the First Islet Cell Transplantation — 4; 1 participants
N/A N=14 Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation
Chronic Pancreatitis · Diabetes Mellitus
Primary: Study Period: Average Serum BG — 130; 111 mg/dL — p=0.003
Phase 4 N=29 Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
Kidney Transplant · Diabetes Mellitus, Type 2 · Diabetic Nephropathy
Primary: Freedom From Insulin Therapy Post Transplant — 3; 4 Participants
Phase 2 N=11 Fat Malabsorption in Chronic Pancreatitis
Chronic Pancreatitis
Primary: Malabsorption Blood Test: Difference in Mean HA AUC Between Groups: Subjects With CP Compared to Healthy Subjects — 8.3; 17.7 mg*h/dL — p=<0.001
N/A N=26 Effect of Chronic Incretin-based Therapy in Cystic Fibrosis
Cystic Fibrosis · Pancreatic Insufficiency
Primary: Change in Second-phase Insulin Response Derived From the Glucose-potentiated Arginine Test as a Measure of β-cell Sensitivity to Glucose at Baseline and at 6 Months…
Phase 2 N=3 Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation
Type 1 Diabetes Mellitus
Primary: Measurement of Glycemic Control by HbA1c and Prevention of Severe Hypoglycemia — 3 participants
Phase 2 N=10 Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression
Diabetes Mellitus, Type 1
Primary: Number of Participants With Adverse Events Including Laboratory Abnormalities at the End of Study Participation — 4; 5 participants
N/A N=101 Role of Pancreatic Triglyceride Content in Beta-cell Function
Obesity · Type 2 Diabetes
Primary: Pancreatic and Liver Fat — 1.87; 6.57; 3.61; 5.85 percent
N/A N=57 MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics
Healthy Volunteers
Primary: Total Secreted Fluid Volume as Measured by MR-PFT — 79 mL
N/A N=14 Pancreatic Endotherapy for Refractory Chronic Pancreatitis
Pancreatic Duct Stone · Pancreatic Duct Stricture · Pancreatic Duct Dilatation
Primary: Percent Change in Average Daily Pain Score on the Numeric Rating Scale — -36.6; -53.7 Percent Change
Phase 2 N=9 Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation
Pre Diabetes
Primary: Progression From Prediabetes to Diabetes — 0; 1 Participants